Huang J, Yu Y, Lin W, Zhang D, Deng Z, Ding Q. Olanzapine-induced peripheral eosinophilia and eosinophilic pleural effusion: A case report.
Medicine (Baltimore) 2018;
97:e9996. [PMID:
29443793 PMCID:
PMC5839811 DOI:
10.1097/md.0000000000009996]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
RATIONALE
Eosinophilic pleural effusion (EPE) is an eosinophil count ≥10% in pleural effusion, which is a rare condition in drug therapy.
PATIENT CONCERNS
We describe the case of a 70-year-old Alzheimer patient who was taking olanzapine for 2 months for the treatment of depression, and developed peripheral eosinophilia and bilateral EPE.
DIAGNOSES
Olanzapine-induced peripheral eosinophilia and eosinophilic pleural effusion was diagnosed.
INTERVENTIONS
Olanzapine was discontinued, and repeated drainage of fluid from the pleural cavity was performed.
OUTCOMES
All symptoms-as well as the EPE-were resolved 6 months later.
LESSONS
This case is a reminder that olanzapine may be a potential agent for EPE, and that this should be considered in clinical practice.
Collapse